Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This combination drug is an oral medication indicated for the treatment of symptoms associated with lower urinary tract infections and irritations, such as pain, burning, and frequency. It is also used to relieve discomfort following diagnostic procedures. The formulation contains five active components: methenamine, which acts as a prodrug that converts to the bactericidal agent formaldehyde in acidic urine; sodium phosphate, which serves as a urinary acidifier to facilitate methenamine's conversion; hyoscyamine, an antispasmodic that antagonizes muscarinic acetylcholine receptors to reduce bladder spasms; phenyl salicylate, which provides mild analgesic and antiseptic effects; and methylene blue, a weak antiseptic. This multi-modal approach addresses both the underlying bacterial presence and the symptomatic spasms and pain associated with urinary tract conditions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on methenamine + sodium phosphate + phenyl salicylate + methylene blue + hyoscyamine.